- Home
- WLYB vs CELC Comparison
WLYB vs CELC Comparison
Compare WLYB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- CELC
- Stock Information
- Founded
- WLYB 1807
- CELC 2011
- Country
- WLYB United States
- CELC United States
- Employees
- WLYB N/A
- CELC N/A
- Industry
- WLYB Books
- CELC Medical Specialities
- Sector
- WLYB Consumer Discretionary
- CELC Health Care
- Exchange
- WLYB Nasdaq
- CELC Nasdaq
- Market Cap
- WLYB 2.1B
- CELC 2.3B
- IPO Year
- WLYB N/A
- CELC 2017
- Fundamental
- Price
- WLYB $40.69
- CELC $49.50
- Analyst Decision
- WLYB
- CELC Strong Buy
- Analyst Count
- WLYB 0
- CELC 6
- Target Price
- WLYB N/A
- CELC $63.00
- AVG Volume (30 Days)
- WLYB 817.0
- CELC 1.0M
- Earning Date
- WLYB 09-04-2025
- CELC 11-13-2025
- Dividend Yield
- WLYB 3.63%
- CELC N/A
- EPS Growth
- WLYB N/A
- CELC N/A
- EPS
- WLYB 1.78
- CELC N/A
- Revenue
- WLYB $1,670,600,000.00
- CELC N/A
- Revenue This Year
- WLYB $1.45
- CELC N/A
- Revenue Next Year
- WLYB $2.70
- CELC N/A
- P/E Ratio
- WLYB $21.17
- CELC N/A
- Revenue Growth
- WLYB N/A
- CELC N/A
- 52 Week Low
- WLYB $37.17
- CELC $7.58
- 52 Week High
- WLYB $52.90
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- WLYB 50.92
- CELC 48.81
- Support Level
- WLYB $40.02
- CELC $47.43
- Resistance Level
- WLYB $42.33
- CELC $50.74
- Average True Range (ATR)
- WLYB 0.03
- CELC 2.91
- MACD
- WLYB 0.15
- CELC -0.96
- Stochastic Oscillator
- WLYB 59.71
- CELC 40.20
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.